Chemotherapy and resection for colorectal metastases

The Lancet Oncology

Volumn 14, Issue 12, 2013, Pages 1148-1149

  Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

CANCER ADJUVANT THERAPY; COLORECTAL LIVER METASTASIS; HEALTH CARE ACCESS; HUMAN; INTERMETHOD COMPARISON; LETTER; LIVER METASTASIS; LIVER RESECTION; LONG TERM SURVIVAL; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; NEOADJUVANT THERAPY;

EID: 84886717888     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70478-9     Document Type: Letter

References (10)

1. Ito K, Govindarajan A, Ito H, Fong Y Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J 2010, 16:103-110.
2. Wicherts DA, Miller R, de Haas RJ, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008, 248:994-1005.
3. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators.
4. Mansour J, Fong Y Timing of the liver resection for patients with synchronous metastases: practical and outcome considerations. Ann Surg Oncol 2007, 14:2435-2436.
5. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016. for the EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UKCancer Research UK, ArbeitsgruppeLebermetastasen und-tumoren in der ChirurgischenArbeitsgemeinschaftOnkologie (ALM-CAO)ArbeitsgruppeLebermetastasen und-tumoren in der ChirurgischenArbeitsgemeinschaftOnkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG)Australasian Gastro-Intestinal Trials Group (AGITG), and Fédération Francophone de Cancérologie Digestive (FFCD)and Fédération Francophone de Cancérologie Digestive (FFCD).
6. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013, published online October 11. http://dx.doi.org/10.1016/S1470-2045(13)70447-9.
7. Fortner JG, Fong Y Twenty-five-year follow-up for liver resection: the personal series of Dr Joseph G Fortner. Ann Surg 2009, 250:908-913.
8. Allegra CJ, Yothers G, O'Connell MJ, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013, 31:359-364.
9. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012, 13:1225-1233.
10. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012, 307:1383-1393.